Warner Pharmaceuticals announced that its wholly-owned subsidiary Hunan Warner Pharmaceutical Co., Ltd. received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for arginine ibuprofen issued by the State Drug Administration and published it on the CDE platform. Arginine ibuprofen is an anti-inflammatory analgesic. It is suitable for pain symptoms such as toothache and dysmenorrhea. It can inhibit prostaglandin synthesis and has analgesic, antipyretic and anti-inflammatory effects. The approval of this API will further enrich the company's product line and enhance its core competitiveness. Currently, there are no sales of APIs. Production and sales times are uncertain. Drug sales are easily affected by factors such as policies and market environments, and there are risks.